ACELYRIN, INC. Common Stock Total Liabilities
ACELYRIN, INC. Common Stock total liabilities. Based on the latest financial reports, ACELYRIN, INC. Common Stock (SLRN) has total liabilities worth $29.27 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ACELYRIN, INC. Common Stock (SLRN) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of ACELYRIN, INC. Common Stock (2021–2024)
Total liabilities of ACELYRIN, INC. Common Stock from 2021 to 2024. This chart illustrates how ACELYRIN, INC. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
ACELYRIN, INC. Common Stock Competitors by Total Liabilities
The table below lists competitors of ACELYRIN, INC. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Viking Supply Ships AB (publ)
ST:VSSAB-B
|
Sweden | Skr1.73 Billion |
|
Beetaloo Energy Australia Limited
AU:BTL
|
Australia | AU$40.05 Million |
|
Guangdong Weide Information Technology Co. Ltd. A
SHG:688171
|
China | CN¥72.67 Million |
|
HAXC Holdings (Beijing) Co. Ltd.
SHE:300928
|
China | CN¥178.42 Million |
|
Hawthorn Bancshares Inc
NASDAQ:HWBK
|
USA | $1.72 Billion |
|
Dustin Group AB
ST:DUST
|
Sweden | Skr7.71 Billion |
|
CammSys Corp
KQ:050110
|
Korea | ₩129.26 Billion |
|
Baoding Dongli Machinery Co.Ltd.
SHE:301298
|
China | CN¥290.11 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down ACELYRIN, INC. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ACELYRIN, INC. Common Stock assets under control.
Liquidity & Leverage Metrics
ACELYRIN, INC. Common Stock Total Liabilities Ratios Explained
ACELYRIN, INC. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 18.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.07 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ACELYRIN, INC. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ACELYRIN, INC. Common Stock (2021–2024)
The table below shows the annual total liabilities of ACELYRIN, INC. Common Stock from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $32.85 Million | -61.96% |
| 2023-12-31 | $86.35 Million | -80.57% |
| 2022-12-31 | $444.35 Million | +207.81% |
| 2021-12-31 | $144.36 Million | -- |
About ACELYRIN, INC. Common Stock
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, which has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED). Acelyrin, Inc. was incorp… Read more